Every finding on record at Stch Moline Opco LLC

It is required that the documented comprehensive assessment includes a drug profile that contains the patient's current: prescription and over-the-counter (OTC) drugs; supplements; herbal remedies; [and] other alternative treatments that could affect drug therapy. The medication review process includes the identification of the following: the effectiveness of drug therapy; drug side effects; actual or potential drug interactions; duplicate drug therapy; [and] drug therapy associated with laboratory monitoring. The assessment includes evidence that common side effects of medication in the hospice populations are anticipated, and, as appropriate, preventive measures are implemented to manage the side effects. The drug profile is updated per the hospice policy and procedure, but, at minimum, at the time of each comprehensive assessment and/or when new medication is added or changes are made to existing medication. This standard was not met as evidenced by clinical record review, interview, and observation. In 1 of 3 (33%) home visits observed and clinical records reviewed, the agency did not ensure that the comprehensive assessment included a drug profile that contained the patient's current medications. HOME VISIT 3/CLINICAL RECORD 3: This patient elected the hospice benefit on 10/14/2025 with a terminal diagnosis of chronic obstructive pulmonary disease (COPD). The patient resided in a skilled nursing facility (SNF). During the home visit with the Hospice Aide (HA) [Personnel Record 10] on 11/04/2025, the hospice medication profile (printed 11/03/2025) and the SNF medication profile dated 11/04/2025 were reviewed. The SNF medication profile documented: Calazime to the buttocks twice a day, and ferrous sulfate oral tablet 325 mg (65 mg iron), one (1) tablet by mouth twice a day. The hospice drug profile did not document Calazime or ferrous sulfate. The hospice drug profile documented Senna Laxative 8.6 mg tablet, one (1) tablet as needed daily, and Xifaxan 550 mg, one (1) tablet two times daily. The SNF drug profile did not document Senna Laxative or Xifaxan. During a joint record review and interview on 11/04/2025, the Regional Director of Clinical Operations/Administrator/Director of Nursing stated there was no documented evidence that the medications were reconciled at the time of each comprehensive assessment and updated to the drug profile, stating that the Registered Nurse/Case Manager (RNCM) was educated to ensure that the hospice drug profiles were updated and reconciled with the facility's drug profile.